The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Pathological response as a predictor for adjuvant FLOT efficacy in gastroesophageal cancer
Radka Obermannova, MD, PhD, Masaryk University, Brno, Czech Republic, comments on findings from a real-world study (ACTRN12622000180718) assessing whether pathological response to neoadjuvant FLOT can guide its adjuvant use in locally-advanced gastroesophageal adenocarcinoma. Only partial responders to neoadjuvant FLOT showed significant benefit from adjuvant FLOT in terms of disease-free survival (DFS) and overall survival (OS). Minimal and complete responders did not have a significant survival advantage from adjuvant therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
